-+ 0.00%
-+ 0.00%
-+ 0.00%

enGene Q2 FY26 net loss widens to USD 30.23 million

PUBT·06/15/2026 13:01:53
Listen to the news
enGene Q2 FY26 net loss widens to USD 30.23 million
  • enGene posted a net loss attributable to common shareholders of USD 30.2 million, or USD 0.43 per share, for Q2 ended April 30.
  • Total operating expenses rose to USD 32 million from USD 27.1 million a year earlier; R&D climbed to USD 22.2 million.
  • Cash, cash equivalents and marketable securities totaled USD 285.2 million as of April 30.
  • LEGEND Cohort 1 interim data showed a 54% complete response rate at any time; FDA BLA discussions planned for 2H 2026.
  • Workforce cut by about 50% to preserve cash; CFO Ryan Daws, CLO Lee Giguere, CSOO Alex Nichols to depart July 15.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260615436479) on June 15, 2026, and is solely responsible for the information contained therein.